ArticleAngewandte Chemie (International ed. in English)2026
Perilipin-2-Anchored Lipid Droplet-Targeting Phototheranostics.
Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Conventional photothermal agents are readily taken up by normal cells, which may cause off-target damage. Lipid droplet (LD) targeting can enable photothermal agents to accumulate in tumor cells enriched in LDs, a central hub for lipid storage. We herein report an LD-targeted theranostic agent, C-BDP-OMe, through a dual-anchoring strategy that combines the principle of "like dissolves like" with specific docking to the PLIN2 protein. Structurally, C-BDP-OMe features an extended conjugated system and an asymmetric coumarin-fused BODIPY scaffold, enabling NIR-region optical properties, a large Stokes shift, and high photostability. The probe exhibits polarity-sensitive behavior, with turn-on fluorescence and a high signal-to-noise ratio under no-wash conditions. Furthermore, C-BDP-OMe demonstrates robust photothermal performance, with a photothermal conversion efficiency of 62.6%, enabling localized photothermal ablation and resulting in effective tumor suppression while avoiding systemic side effects. The therapeutic mechanism was systematically investigated and shown to involve the concurrent activation of two distinct cell death pathways-apoptosis and ferroptosis. This work highlights the therapeutic value of subcellular organelle-level precision interventions and underscores the importance of exploiting subtle microenvironmental features in the design of next-generation anticancer theranostic agents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.